NCT02150213 2016-12-05Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492NovartisPhase 2 Completed59 enrolled 6 charts
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled